Sana Biotechnology Inc vs iShares Semiconductor ETF — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while iShares Semiconductor ETF trades at $550.62. The key difference: iShares Semiconductor ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SOXX | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $655.01 |
52-Week Low | $2.68 | $241.68 |
Enterprise Value | $1.05B | — |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
SOXX trades at $546.61, up 3.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. Support lies near $530 and resistance at $548. Recent news highlights sector volatility, including a 21% drop in July 2026 due to headwinds like short-seller commentary and competitive pressures, though cloud company growth supports AI spending optimism.
The outlook is mixed: strong AI demand from cloud providers offers upside, but concentration risk and tariff uncertainties pose threats. Investors face volatility from sector rotations and geopolitical factors, requiring careful risk assessment amid evolving semiconductor dynamics.
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →